Loading

Slzii.com Search

Search (News)

U.S. FDA Grants Reunion Neuroscience's Luvesilocin (RE104) Breakthrough Therapy Designation Status
(MENAFN - GlobeNewsWire - Nasdaq) -- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U.S. Food and Drug Administration on Registrational Path for ...
2026-02-23 07:31:30

What are you doing?

0.040098190307617


News
News

Latest News and Headlines
(MENAFN - GlobeNewsWire - Nasdaq) -- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U....
News